Looking Into Trevena’s Return On Capital Employed
Trevena (NASDAQ:TRVN) brought in sales totaling $-1.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 1.32%, resulting in a loss of $13.95 million.
Recap: Trevena Q4 Earnings
Trevena (NASDAQ:TRVN) reported its Q4 earnings results on Thursday, March 31, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings Scheduled For March 31, 2022
Companies Reporting Before The Bell
• Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter.
12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers
Cidara Therapeutics (NASDAQ:CDTX) stock moved upwards by 14.1% to $0.91 during Thursday's after-market session. The company's market cap stands at $60.6 million.
Trevena Announces Submission Of New Drug Application In China For OLINVYK By Its Partner Jiangsu Nhwa Pharmaceutical
Submission supported by data from a Phase 3 bridging study of oliceridine injection compared to IV morphine, conducted in China by Nhwa
Trevena is eligible to receive future success payments upon approval and
Trevena Announces Advancement Of TRV045 Into Clinical Development For Diabetic Neuropathic Pain
Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced it is advancing